Sprout Group

Sprout Group, a venture capital and private equity investment firm, specializes in growth capital, buyouts, and recapitalization investments, with a primary focus on start-ups in emerging technology, healthcare technology, communications, and software sectors. Founded in 1969 and based in New York, New York, with additional offices in Palo Alto and Menlo Park, California, Sprout Group has financed over 350 companies and raised nearly $3.0 billion in committed capital. Although they are no longer actively investing, Sprout Group frequently served as the lead investor in its portfolio companies, providing investments ranging from $10 million to $50 million per portfolio company. Operating as a subsidiary of Credit Suisse Private Equity, LLC, Sprout Group remains a significant player in the venture capital landscape.

Janet Hickey

Co-Managing Partner

122 past transactions

Evolution Benefits

Series B in 2003
Evolution Benefits simplify the business of healthcare through innovative healthcare software and payment solutions that administer and manage consumer directed accounts and exchange integration solutions, such as defined contribution plans, HSAs, HRAs, FSAs, VEBAs, PRAs, wellness plans, and transit plans.

Reliance Globalcom

Venture Round in 2006
Reliance Globalcom, a division of Reliance Communications, spearheads the Global Telecom operations of India's largest Integrated Telecom Service Provider. Reliance Globalcom brings together the synergies of Reliance Communications Global Business encompassing Enterprise Services, Capacity Sales, Managed Services and a highly successful bouquet of Retail products & services comprising of Global Voice, Internet Solutions and Value Added Services. The company serves over 2100 enterprises, 200 carriers and 2.2 million retail customers in 163 countries across 6 continents.

SupplySolution

Venture Round in 2000
Supply Solutions is an online based company selling industrial supplies.

NeuroVista

Series B in 2007
NeuroVista Corporation, a medical device company, develops medical technologies for the management and treatment of epilepsy in the United States. It offers advisory technologies to help mitigate the uncertainty of when epileptic seizures may strike. The company was formerly known as BioNeuronics Corporation and changed its name to NeuroVista Corporation in May 2007. NeuroVista Corporation was incorporated in 2002 and is based in Seattle, Washington.

OmniSky

Series B in 2000
In January 2002, OmniSky Corporation sold substantially all of its assets to EarthLink, Inc., including its subscriber base, all of its intellectual property rights, and key network assets, pursuant to its filing for Bankruptcy. The company prior to selling its assets was a global developer and provider of wireless data applications and services for users of mobile devices.

Silicon Access Networks

Series D in 2002
Silicon Access Networks is a provider of an ultra-high performance chipsets for terabit routers and communication silicon to the networking and telecommunications market.

Soapstone Networks

Series C in 1999
Soapstone Networks (formerly Avici Systems) developer of Terabit Switch/Router technology aimed at providing the next generation of high performance, IP-based routers to carriers and Internet Service Providers worldwide. Soapstone Networks got liquidated in 2009 July.

iAsiaworks

Venture Round in 1999
iAsiaWorks Inc. operates data centers that offers dedicated hosting, co-location, and managed services to businesses in Asia and internationally. iAsiaWorks Inc. was formerly known as AUNET Corporation and changed its name to iAsiaWorks Inc. in December 1999. The company was incorporated in 1995 and is based in San Mateo, California.

Sensys Medical

Series D in 2002
Sensys Medical develops a non-invasive blood glucose monitor that used near-infrared diffuse reflectance spectroscopy.

Infinera

Series D in 2003
Optical networking systems based on photonic integration technology in the united states

Gryphon Therapeutics

Series B in 2002
Gryphon Therapeutics is a biopharmaceutical company focused on the development of performance-enhanced protein therapeutics. Its products combine chemically synthesized protein backbones with polyethylene glycols such as molecules to create potent medications.

Variagenics

Funding Round in 2000
Variagenics develops and commercializes proprietary gene variance detection technology to streamline drug development.

Epotec

Venture Round in 1999
Epotec has harnessed the resources of the Internet to enhance the effectiveness of behavioral health services. Founded in 1997, Epotec combines ingenuity and technology in creating Web-based interactive programs that help people lead happier, more productive lives by building skills and solving problems – securely and privately.

Storability Software

Series B in 2001
Storability Software is a provider of enterprise storage resource management solutions that simplify and centralize the management of complex, multi-site, multi-vendor storage infrastructures. Storability Software's Global Storage Manager is an open standards-based solution that enables customers to comprehend, control, and capitalize on their storage investment as never before. Customers benefit from increased asset utilization, improved management efficiency, enhanced quality of service, and higher availability.

CareDx

Series E in 2005
Founded in 2000, XDx, Inc. is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products under development. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored.

Alcatel Communications

Series B in 1999
Astral Point Communications develops transmission network elements aimed at metropolitan optical access to the internet.

Auxilium Pharmaceuticals

Series D in 2003
Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health. While we remain dedicated to this founding principle, Auxilium’s mission has expanded to include the development and marketing of novel treatment options for many of society’s unmet medical needs.

CellGate

Series E in 2003
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).

Kalypsys

Series B in 2004
Kalypsys provides pathway-based drug discovery and development services. The company implements discovery programs across a broad number of therapeutic areas using its automated and integrated suite of discovery technologies in biology, chemistry and informatics.

Lefthand Networks

Series C in 2003
Provider of data storage systems and ip-based storage area networks

Sirna Therapeutics

Venture Round in 2003
The scientific community considers RNA interference the breakthrough biological discovery of the decade with the potential to change how diseases are treated. Sirna Therapeutics is at the forefront of the effort to create RNAi- based therapies and leverage the vast potential of this technology to ultimately treat patients.

Ilypsa

Series A in 2003
It discovers and develops renal care pharmaceutical products. It develops non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney diseases. The company, formerly known as Symyx Therapeutics, Inc. was founded in 2002 and is based in Santa Clara, California.

Storability Software

Series D in 2003
Storability Software is a provider of enterprise storage resource management solutions that simplify and centralize the management of complex, multi-site, multi-vendor storage infrastructures. Storability Software's Global Storage Manager is an open standards-based solution that enables customers to comprehend, control, and capitalize on their storage investment as never before. Customers benefit from increased asset utilization, improved management efficiency, enhanced quality of service, and higher availability.

TradeBeam

Venture Round in 2009
TradeBeam, a Global Trade Management software and services company, streamlines global trading processes for enterprises and their partners. Comprehensive, integrated solutions delivered via the on-demand SaaS model provide import and export compliance, inventory management, shipment tracking, supply chain event management, and global trade finance solutions.

CareDx

Series G in 2009
Founded in 2000, XDx, Inc. is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products under development. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored.

CallFixie

Seed Round in 2016
CallFixie Pty Ltd. develops a Website and mobile application for home repair and maintenance services. Its platform connects customers with tradesmen, who provide air conditioning, cleaning, carpentry, electrical, plumbing, landscaping, locksmith works, general works, and other works. The company serves F&Bs, furniture retailers, electrical brands, real estate managers, and households. CallFixie Pty Ltd. was incorporated in 2014 and is based in South Yarra, Australia.

Spotfire

Series B in 1999
TIBCO Software empowers executives, developers, and business users with Fast Data solutions that make the right data available in real time for faster answers, better decisions, and smarter action. Over the past 15 years, thousands of businesses across the globe have relied on TIBCO technology to integrate their applications and ecosystems, analyze their data, and create real-time solutions. Learn how TIBCO turns data—big or small—into differentiation at www.tibco.com.

Epocrates

Series B in 2000
Epocrates develops mobile and online clinical information and decision support software that enables health-care professionals to find answers more quickly and confidently at the point of care. 1 out of 3 U.S. physicians and 1 out of 3 U.S. medical students currently use Epocrates software.

OneClip.com

Venture Round in 2000
OneClip.com, a secure Internet promotion clearinghouse.

Spotfire

Series C in 2000
TIBCO Software empowers executives, developers, and business users with Fast Data solutions that make the right data available in real time for faster answers, better decisions, and smarter action. Over the past 15 years, thousands of businesses across the globe have relied on TIBCO technology to integrate their applications and ecosystems, analyze their data, and create real-time solutions. Learn how TIBCO turns data—big or small—into differentiation at www.tibco.com.

Relypsa

Series A in 2007
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Calix

Venture Round in 2009
Calix is a global provider of the cloud and software platforms, systems and services to deliver unified access networks and smart premises systems. Innovative communications service providers rely on Calix to help them master and monetize the complex infrastructure between their subscribers and the cloud. Calix customers leverage our intelligent software platforms and cloud analytics to transform and optimize their business models, rapidly deploy new services at DevOps speed, and make the promise and opportunity of the smart home and business a reality. Calix customers include Verizon, ALLO Communications, CityFibre, Nex-Tech, Gibson Connect, ITS Fiber and over 1,400 other communications service providers globally, majority being in North America.

Relypsa

Private Equity Round in 2012
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Aureon Laboratories

Series D in 2010
Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools.

Direct Flow Medical

Series A in 2005
Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

Yipes

Series C in 2005
Yipes is a data communications services provider. It was acquired in 2007 by Indian telecommunications service provider Reliance Communications. Yipes delivers scalable business-to-business and business-to-Internet IP networking services. Their regional IP network Yipes MAN seamlessly extends your company's LAN to other business locations or to business partner locations. Their Yipes NET Internet service brings the Web to your LAN at breakaway speeds. Yipes NET customers can also take advantage of Yipes' industry-leading security offering Yipes WALL managed firewall service, to safeguard their private information from the dangers of the public Internet. Yipes NAN replaces private line and frame relay services with the simplicity of Ethernet. Yipes WEB offers a full portfolio of Internet management services. Yipes TOUGH enables customers to extend the redundancy on their customer premise to the Yipes Network.

DynamicSoft

Series C in 2002
DynamicSoft provides carrier-class infrastructure software for packet-based wireline and wireless communications networks. The company's infrastructure solutions enable carriers and communications application service providers to deploy telephony applications and converged services over Internet protocol-based networks. Its dynamicsoft Service Engine allows mobile carriers to deliver voice and data services over packet network, as well as provides a migration path to various IP 3G network environments; supports various services, such as voice, multimedia messaging, instant messaging, and presence; and consolidates common functions, which include customer data storage, authentication, authorization, provisioning, and service interaction. The company was founded in 1998 and is based in East Hanover, New Jersey.
Aspreva Pharmaceuticals Corp is an emerging pharmaceutical company headquartered in Victoria, British Columbia focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. Their strategy, which they call “indication partnering”, is to collaborate with pharmaceutical and biopharmaceutical companies to pursue new indication approvals which lie beyond their strategic focus.

Skila

Venture Round in 2000
Skila is an internet company providing business intelligence and eKnowledge solutions for the pharmaceutical and biotechnology industries.

NetCore Systems

Venture Round in 1998
NetCore Systems develops and markets innovative switching technology for the core of the new Internet. NetCore's products enable Internet Service Providers (ISPs) and carriers to construct a large-scale multi-service core network with the guaranteed performance levels and reliability that businesses need.

Internet Photonics

Series C in 2002
Internet Photonics, Inc. is an innovative growth company delivering the first carrier-grade Intelligent Wavelength Platforms, which allow network operators (service providers and cable MSOs) to sell profitable high-bandwidth data services alongside existing legacy services.

Aureon Laboratories

Series B in 2005
Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools.

Aurora Networks

Series B in 2002
Aurora develops optical transport equipment for HFC, or hybrid fiber coaxial cable networks, which are the networks of choice for cable TV operators.

Alcatel Communications

Series C in 2000
Astral Point Communications develops transmission network elements aimed at metropolitan optical access to the internet.

Edupoint

Series B in 2000
Edupoint’s Synergy® Education Platform is a fully-integrated data management solution for K-12, with Synergy SIS, the industry’s most powerful student information system, Synergy LMS for learning management and assessment, and Synergy SE for comprehensive special education management.

MuseumShop

Series B in 2000
MuseumShop.com has established partnerships and affiliations with more than 44 museums worldwide and showcases more than 3,500 products ranging from home decor to fine prints.

CareDx

Series D in 2004
Founded in 2000, XDx, Inc. is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products under development. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored.

DynamicSoft

Series B in 2000
DynamicSoft provides carrier-class infrastructure software for packet-based wireline and wireless communications networks. The company's infrastructure solutions enable carriers and communications application service providers to deploy telephony applications and converged services over Internet protocol-based networks. Its dynamicsoft Service Engine allows mobile carriers to deliver voice and data services over packet network, as well as provides a migration path to various IP 3G network environments; supports various services, such as voice, multimedia messaging, instant messaging, and presence; and consolidates common functions, which include customer data storage, authentication, authorization, provisioning, and service interaction. The company was founded in 1998 and is based in East Hanover, New Jersey.

Relypsa

Series C in 2012
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

BravoGifts.com

Series B in 2000
BravoGifts.com is the first e-commerce site tailored exclusively to the needs of the business gift market. BravoGifts.com provides the highest levels of service to its customers through: selection - the widest selection of business gifts available anywhere; gift advice and services - advice and information on business gifts, gift searching, unique gift selection tools, and business gift etiquette; and convenience - everything is centralized in one easily accessible Internet location. The company boasts the broadest collection of brilliant business gifts from executive toys and gadgets, to golf and weekend getaways, theater and sports tickets, and gourmet foods.

Reliance Globalcom

Venture Round in 2005
Reliance Globalcom, a division of Reliance Communications, spearheads the Global Telecom operations of India's largest Integrated Telecom Service Provider. Reliance Globalcom brings together the synergies of Reliance Communications Global Business encompassing Enterprise Services, Capacity Sales, Managed Services and a highly successful bouquet of Retail products & services comprising of Global Voice, Internet Solutions and Value Added Services. The company serves over 2100 enterprises, 200 carriers and 2.2 million retail customers in 163 countries across 6 continents.

Relypsa

Series B in 2011
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Kalypsys

Series A in 2002
Kalypsys provides pathway-based drug discovery and development services. The company implements discovery programs across a broad number of therapeutic areas using its automated and integrated suite of discovery technologies in biology, chemistry and informatics.

Silicon Access Networks

Series B in 2000
Silicon Access Networks is a provider of an ultra-high performance chipsets for terabit routers and communication silicon to the networking and telecommunications market.

Sopherion

Series B in 2004
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Vasca

Venture Round in 2000
Vasca is a medical device company that provides technologies to improve body access for therapeutic interventions in the United States and European Union. The company develops, manufactures, and markets LifeSite, a subcutaneous device that combines a valve with cannulas, which are used for the treatment of chronic renal failure. Vasca was founded in 1996 and is based in Tewksbury, Massachusetts, United States.

Yipes

Series B in 2000
Yipes is a data communications services provider. It was acquired in 2007 by Indian telecommunications service provider Reliance Communications. Yipes delivers scalable business-to-business and business-to-Internet IP networking services. Their regional IP network Yipes MAN seamlessly extends your company's LAN to other business locations or to business partner locations. Their Yipes NET Internet service brings the Web to your LAN at breakaway speeds. Yipes NET customers can also take advantage of Yipes' industry-leading security offering Yipes WALL managed firewall service, to safeguard their private information from the dangers of the public Internet. Yipes NAN replaces private line and frame relay services with the simplicity of Ethernet. Yipes WEB offers a full portfolio of Internet management services. Yipes TOUGH enables customers to extend the redundancy on their customer premise to the Yipes Network.

Mouawad

Series B in 2000
Mouawad is a multinational jewelry and timepiece company that sources diamonds and gemstones, designs, manufacturers, and sells jewelry collections, objects of art, and luxury watches. It has penetrated continents across the world, while retaining its position as jewelers to royalty, high society, celebrities, and more. The company offers a wide range of jewels and timepieces for all occasions. In addition to its jewelry and timepiece design and production, Mouawad also manufacturers rough diamonds as a Diamond Trading Company Sightholder through its joint venture company, Premier Diamond Alliance. Its family’s on-going support of the global industry through research and education led to third generation, Robert Mouawad, receiving a Lifetime Achievement Award from the Gemological Institute of America and of having the GIA campus named in his honor. Guinness has honored Mouawad on three occasions with world records: in 2010, for the Mouawad 1001 Nights Diamond Purse, the most valuable handbag in the world; in 2003, for the Very Sexy Fantasy Bra, the most luxurious and expensive piece of lingerie ever made; and in 1990, for the Mouawad Splendor, at the time, the most expensive single pear-shaped diamond in the world. Mouawad was founded in 1890 by [Fred Mouawad](https://www.crunchbase.com/person/fred-mouawad#/entity) and is based in Dubai. It operates boutiques in Jordan, Kuwait, and Lebanon; and distribution offices in Saudi Arabia, Switzerland, Thailand, and the United Arab Emirates.

Barricaid

Series D in 2007
Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.

Lefthand Networks

Series C in 2005
Provider of data storage systems and ip-based storage area networks

Visiogen

Series B in 2002
Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions. The device is designed to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.

Tavolo

Venture Round in 2000
Tavolo offers an online store that enables its users to find and buy products related to cooking. Tavolo was acquired by OurHouse in December 2000. It is based in San Rafael, California.

BrightLink Networks

Series C in 2000
BrightLink Networks, Inc. is a manufacturer of optical network switching systems. The company begins the marketing and manufacturing of its intelligent optical network system.

Opthos

Series B in 2001
Funded in May 2000, Opthos capitalizes on newly-developed, highly innovative technologies. Their goal is to deliver optical networking products that satisfy the overwhelming need by communications carriers for high agility, very low cost solutions.

Excess Bandwidth

Series B in 2000
Excess Bandwidth Corp. develops algorithms that enable the connection of Internet voice and data services to multiple appliances over copper twisted-pair wires, and implements those algorithms in high-performance integrated circuits. It is the first company to develop technology that fully meets the G.shdsl/HDSL2 high-speed symmetric DSL (digital subscriber line) specification (defined by international standards bodies) for transmitting high-speed voice and data over a single pair of wires. Founded in 1998, Excess Bandwidth is a privately held, venture capital-funded company.

CarrierPoint

Series B in 2000
CarrierPoint designs and develops web-based logistics software that enables shippers and carriers to communicate with each other. The company’s range of solutions consists of compliance, monitoring, collaboration, and integration. Compliance offers eRFQ, contract management, shipment rating, dispatch, scheduling, and freight payment services. Monitoring offers status tracking, delivery confirmation, dock delivery, and analysis reports. Collaboration consists of planned and unplanned collaboration. Integration consists of OMSI and professional services. CarrierPoint was founded in 1999 by Cliff Isaacson and John Thomson and is based in Georgia.

eFinance.com

Series A in 2000
eFinance's innovative solutions enable companies to quickly and accurately gauge the financial soundness of their customers at each step of the financial supply chain. Their solutions strengthen the credit evaluation process and enable customers to better manage transaction workflow. Customers leverage eFinance technology to increase revenue and profitability while expanding their end customer base and improving customer retention and satisfaction.

Affymax

Series D in 2005
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematideâ„¢), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA).

Labcyte

Series B in 2002
Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.

Labcyte

Series C in 2008
Lab­cyte Inc. is a lab­o­ra­tory instru­men­ta­tion com­pany with a novel approach to dis­pens­ing small vol­umes of liq­uids for life sci­ences appli­ca­tions. The company's acoustic dis­pens­ing tech­nol­ogy uses a focused beam of acoustic energy to eject nanoliter-​​scale droplets of fluid from one plate to another, with high accu­racy at low vol­umes and reduced con­sum­ables costs. In addi­tion to DBL Investors, investors include Alloy Ven­tures, Abing­worth, New Leaf Ven­ture Part­ners, and Cross Atlantic Partners. Labcyte was founded in 2000 and is based in San Jose, California, United States.

Spiration

Series D in 2002
Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

NeuroVista

Series A in 2004
NeuroVista Corporation, a medical device company, develops medical technologies for the management and treatment of epilepsy in the United States. It offers advisory technologies to help mitigate the uncertainty of when epileptic seizures may strike. The company was formerly known as BioNeuronics Corporation and changed its name to NeuroVista Corporation in May 2007. NeuroVista Corporation was incorporated in 2002 and is based in Seattle, Washington.

Atesto Technologies

Series B in 2001
Atesto is an automated Web testing service that enables organizations to develop, deploy and monitor Web applications without needing to license, install and manage software and hardware systems and infrastructure. The company’s software suite, Atesto Functional Test, tests and validates complex, static and dynamic Web applications. The company also offers load testing and monitoring services, to address performance and application maintenance needs. The Automated Load Test services simulate complex real-life application scenarios using live Internet traffic from a globally distributed network and the Response Watch service features periodic transaction and Web application monitoring capability from global locations. Both services include detailed, real-time, online reports on application performance and analysis.

Affymax

Series C in 2004
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematideâ„¢), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney disease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA).

Aureon Laboratories

Series A in 2002
Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools.

Visiogen

Venture Round in 2003
Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions. The device is designed to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.

Watercove Networks

Series C in 2003
WaterCove Networks offers the first purpose-built next-generation network solution for wireless service providers seeking to rapidly and cost-effectively deploy profitable mobile data services to meet the needs of their enterprise and consumer customers. The WaterCove Networks Mobile Data Service System allows operators and their partners to accelerate the rollout of value-rich content and "always-on" high-speed data services in 2.5G and 3G GPRS/UMTS and CDMA wireless network environments. Established in 2000 and privately held, WaterCove Networks has introduced the industry's first Mobile Data Service System that overcomes the performance, provisioning, charging, and partnership obstacles inherent in operators' routing-centric legacy networks and equipment. Developed on the groundbreaking FlowCore architecture, the Mobile Data Service System provides a graceful, strategic migration to 2.5G and 3G technologies without the need for costly forklift upgrades. WaterCove Networks is bringing a new generation of ultramobility to life. For more information about WaterCove Networks, please read the company fact sheet. The founders of WaterCove Networks combine extensive experience in the mobile wireless, data networking, telecommunications equipment, and enhanced services industries. The company is led by a seasoned management team accomplished in building and growing emerging technology companies and is guided by a Board of Directors with significant industry experience. WaterCove Networks is backed by $50 million in financing from worldclass investors and is served by an advisory board of industry leaders. Please feel free to contact us for more information about WaterCove Networks, or visit their press room for updated company information. If you are looking for exciting job opportunities with a fast-growing, pre-IPO company, please visit their careers page.

Collective[i]

Series A in 2000
Collective[i] provides a set performance optimization applications, which use a combination of advanced analytics and decision support tools to dramatically improve the performance of your sales, marketing, customer service and customer support teams. Our applications were designed specifically for the business user, not for data experts and analysts. We offer curated, pre-built analyses with simple and intuitive functionality that enables any user, no matter the skill level, to start making data-driven decisions immediately.

LiquidPrice.com

Series B in 2000
LiquidPrice.com is a consumer-driven online marketplace where retailers offer brand name products and services in a competitive environment.

Protedyne Corporation

Venture Round in 2001
In May 2007, Protedyne became a wholly owned subsidiary of Laboratory Corporation of America www.labcorp.com. Protedyne brings serious laboratory automation to LabCorp’s diagnostic testing facilities nationwide. Using the design principles of industrial automation, Protedyne’s automation systems combine powerful laboratory robotic hardware with a software infrastructure that ensures complete data management and process tracking. Protedyne is ISO 13485:2003 Registered with BSI Management Systems.

Barricaid

Series C in 2002
Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.

Evolution Benefits

Venture Round in 2004
Evolution Benefits simplify the business of healthcare through innovative healthcare software and payment solutions that administer and manage consumer directed accounts and exchange integration solutions, such as defined contribution plans, HSAs, HRAs, FSAs, VEBAs, PRAs, wellness plans, and transit plans.

NeuroBionics

Series A in 2004
NeuroBionics Corp. researches and develops medical devices for the treatment of neurological disorders such as Parkinson’s disease, epilepsy, obesity, and depression.

Captura Software

Venture Round in 2000
Captura to provide large companies with comprehensive solutions and services for managing their costs and decreasing processing costs

GroceryWorks

Series A in 2000
In a nutshell, GroceryWorks is your friendly neighborhood online grocery store. They offer over 13,000 brand name items you'd find in your local grocery store, and the list is growing everyday. They are able to bring you the freshest and highest-quality produce, meat, fish, dairy and poultry from the area's finest suppliers. Fruits and vegetables that have never been picked over, or sat on a shelf. The meat and seafood are truly restaurant grade. To top it off, there are chef-prepared meals and a roster of other favorites from eatZi's Market and Bakery. Now, you can have a legendary tiramisu or King Ranch chicken any day of the week and never have to get in your car! The online in their name simply means GroceryWorks is accessible to you, when you want us, 24 hours a day. Their website was designed by shoppers to be easy, intuitive, and yes - fun. You can place your order - all at once or a little at a time, and when you're ready, click to send. They'll be there, delicious groceries in hand, within your selected one hour or two-hour time frame.

Silicon Access Networks

Series C in 2000
Silicon Access Networks is a provider of an ultra-high performance chipsets for terabit routers and communication silicon to the networking and telecommunications market.

SupplySolution

Series D in 2002
Supply Solutions is an online based company selling industrial supplies.

Radiant Medical

Venture Round in 2005
Radiant Medical provides medical devices intended for endovascular temperature therapy. They are a private medical device company pioneering the development of endovascular therapeutic cooling for the treatment of heart, brain, and kidney disorders. It was founded in 1999 and is headquartered in Redwood City, California.